Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/qSXZkyYTmZ

Retrospective study from India on 157 juvenile dermatomyositis (JDM) pts - 44 (28%) had calcinosis. They had a long Dx delay (12 mos), were NXP2+ in 41%, & high risk for Lipodystrophy (39% vs 5%). 39% improved while 61% had static/progressive Dz https://t.co/z5gvqzZV6C https://t.co/9WlzPDZ74w

Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to https://t.co/9dfmKLuJF7

BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001).  1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/BoSgFoOyNN

52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru

Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/OBMdjsegIq

Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/OYTXD4KV6O

Long-term F/U of T2T Artic trial. 230 DMARD naive pts, 84% ACPA+ 179 (82%) in 10 yr F/U & 82% were in DAS < 1.6 remission 10 yrs later w/ only 17% w/ Xray progression. ~50% on csDMARDs, 30% on bDMARDs. Early aggressive works! https://t.co/ASRrIZqfS5 https://t.co/SykEI4QjPa

Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. https://t.co/xPctEjFCLT https://t.co/YIHFaQkzeO

J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/2Tdg96rWFX

Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis Prognostication is tenous in early scleroderma, especially in those with dcSSc. dcSSc has associated with substantial morbidity and disease-specific mortality. Analysis of an early SSc registry shows that anti-RNA https://t.co/Qvu2vSShcg